.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Covington
Healthtrust
US Department of Justice
Mallinckrodt
QuintilesIMS
Harvard Business School
Julphar
Fuji
Medtronic

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,157,121

« Back to Dashboard

Which drugs does patent 9,157,121 protect, and when does it expire?


Patent 9,157,121 protects FANAPT and is included in one NDA. There has been one Paragraph IV challenge on Fanapt.

This patent has ten patent family members in seven countries.

Summary for Patent: 9,157,121

Title:Method of treatment based on polymorphisms of the KCNQ1 gene
Abstract: The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
Inventor(s): Wolfgang; Curt D. (Germantown, MD), Polymeropoulos; Mihael H. (Potomac, MD)
Assignee: Vanda Pharmaceuticals, Inc. (Washington, DC)
Application Number:14/632,914
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-001May 6, 2009ABRXYesYes► Subscribe► Subscribe► SubscribeDOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-002May 6, 2009ABRXYesNo► Subscribe► Subscribe► SubscribeDOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-003May 6, 2009ABRXYesNo► Subscribe► Subscribe► SubscribeDOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-004May 6, 2009ABRXYesNo► Subscribe► Subscribe► SubscribeDOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-005May 6, 2009ABRXYesNo► Subscribe► Subscribe► SubscribeDOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-006May 6, 2009ABRXYesNo► Subscribe► Subscribe► SubscribeDOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-007May 6, 2009ABRXYesNo► Subscribe► Subscribe► SubscribeDOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,157,121

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,999,638Method of treatment based on polymorphisms of the KCNQ1 gene► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,157,121

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan5800798► Subscribe
Japan2015180639► Subscribe
Japan6108633► Subscribe
HungaryE030667► Subscribe
Japan2012522838► Subscribe
Slovenia2417267► Subscribe
Canada2757713► Subscribe
Spain2604102► Subscribe
European Patent Office3023506► Subscribe
European Patent Office2417267► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
QuintilesIMS
Fish and Richardson
Fuji
McKinsey
US Department of Justice
Mallinckrodt
Medtronic
Johnson and Johnson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot